La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

INVO Bioscience Salute del bilancio

Salute finanziaria criteri di controllo 1/6

INVO Bioscience ha un patrimonio netto totale di $1.4M e un debito totale di $2.6M, che porta il suo rapporto debito/patrimonio netto a 193.1%. Le sue attività totali e le sue passività totali sono rispettivamente $18.0M e $16.7M.

Informazioni chiave

193.1%

Rapporto debito/patrimonio netto

US$2.63m

Debito

Indice di copertura degli interessi	n/a
Contanti	US$942.93k
Patrimonio netto	US$1.36m
Totale passività	US$16.67m
Totale attività	US$18.03m

Aggiornamenti recenti sulla salute finanziaria

Recent updates

INVO Bioscience launches INVOcell in Malaysia

Aug 25

INVO BioScience GAAP EPS of -$0.23 beats by $0.01, revenue of $0.14M misses by $0.19M

Aug 15

INVO Bioscience names Andrea Goren as chief financial officer

Jun 15

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( { INVO di $2.4M ) non coprono le sue passività a breve termine ( $8.0M ).

Passività a lungo termine: Le attività a breve termine di INVO ( $2.4M ) non coprono le sue passività a lungo termine ( $8.7M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: Il rapporto debito netto/patrimonio netto ( 123.9% ) di INVO è considerato alto.

Riduzione del debito: Cinque anni fa, INVO aveva un patrimonio netto negativo, ma ora è positivo e quindi è migliorato.

Bilancio

Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: INVO ha meno di un anno di cash runway in base al suo attuale free cash flow.

Previsione Cash Runway: INVO ha meno di un anno di liquidità disponibile se il flusso di cassa libero continua a ridursi ai tassi storici del 30 % ogni anno

INVO Bioscience Salute del bilancio

Salute finanziaria criteri di controllo 1/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

INVO Bioscience Receives Non-Compliance Letter Regarding Nasdaq Listing Rule 5550(a)(2)

INVO Bioscience, Inc. Provides Non-Compliance Update

INVO Bioscience, Inc. Receives Non-Compliance Letter related to Nasdaq Listing Rule 5550(b)(1)

INVO Bioscience, Inc. announced delayed annual 10-K filing

INVO Bioscience Announces Reverse Stock Split to Bring the Company into Compliance with Nasdaq's $1.00 Per Share Minimum Bid Price Requirement for Continued Listing

INVO Bioscience Receives Notice by the Listing Qualifications Department of the Nasdaq Regarding Listing Rule 5550(b)(1)

Recent updates

INVO Bioscience Receives Non-Compliance Letter Regarding Nasdaq Listing Rule 5550(a)(2)

Second quarter 2024 earnings released: US$0.62 loss per share (vs US$3.06 loss in 2Q 2023)

Insufficient new directors

INVO Bioscience, Inc. Provides Non-Compliance Update

INVO Bioscience, Inc. Receives Non-Compliance Letter related to Nasdaq Listing Rule 5550(b)(1)

INVO Bioscience, Inc. announced delayed annual 10-K filing

Forecast to breakeven in 2026

NAYA Biosciences Inc. Announces Publication of New Data for its CD38-targeted Flex-NK Bispecific Antibody in the American Society of Hematology's Blood Journal

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

NAYA Biosciences entered into an agreement to acquire INVO Bioscience, Inc. (NasdaqCM:INVO) in a reverse merger transaction for $9.8 million.

NAYA Biosciences entered into an agreement to acquire INVO Bioscience, Inc. (NasdaqCM:INVO) in a reverse merger transaction for $9.8 million.

Consensus revenue estimates decrease by 24%, EPS upgraded

New major risk - Negative shareholders equity

New major risk - Shareholder dilution

INVO Bioscience, Inc. to Report Q2, 2023 Results on Aug 14, 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

INVO Bioscience, Inc. has completed a Composite Units Offering in the amount of $4.503 million.

INVO Bioscience, Inc. has completed a Composite Units Offering in the amount of $4.503 million.

INVO Bioscience Announces Reverse Stock Split to Bring the Company into Compliance with Nasdaq's $1.00 Per Share Minimum Bid Price Requirement for Continued Listing

INVO Bioscience, Inc. Receives 510(K) FDA Clearance for Expanded Use of the Invocell Device

INVO Bioscience Receives Notice by the Listing Qualifications Department of the Nasdaq Regarding Listing Rule 5550(b)(1)

No longer forecast to breakeven

INVO Bioscience, Inc. to Report Q1, 2023 Results on May 15, 2023

No longer forecast to breakeven

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

INVO Bioscience Receives A Letter from Nasdaq to Grant the Company an Extension of Time to Regain Compliance with Nasdaq Listing Rule 5550(b) Until May 22, 2023

INVO Bioscience Receives a Letter from the Staff of The Nasdaq Stock Market LLC

INVO Bioscience, Inc. announced that it expects to receive $0.275 million in funding

Forecast to breakeven in 2025

INVO Bioscience, Inc. Announces First Baby Born in Malaysia Utilizing Innovative INVOcell Assisted Reproductive Technology

Consensus EPS estimates fall by 31%

INVO Bioscience Receives Non Compliance Notice from Nasdaq

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$2.00

High number of new directors

Price target decreased to US$2.00

High number of new directors

INVO Bioscience, Inc. to Report Q3, 2022 Results on Nov 14, 2022

INVO Bioscience, Inc., Annual General Meeting, Oct 12, 2022

INVO Bioscience launches INVOcell in Malaysia

INVO BioScience GAAP EPS of -$0.23 beats by $0.01, revenue of $0.14M misses by $0.19M

INVO Bioscience, Inc. to Report Q2, 2022 Results on Aug 15, 2022

INVO Bioscience, Inc. to Report Q1, 2022 Results on May 16, 2022

INVO Bioscience Obtains Regulatory Approval to Commercialize INVOcell In Thailand

INVO Bioscience, Inc. (NasdaqCM:INVO) completed the acquisition of Effortless IVF Canada, Inc.

INVO Bioscience, Inc. (NasdaqCM:INVO) entered into a share transfer agreement to acquire Effortless IVF Canada, Inc., from Lyle Oberg, Jason Broome, Richard Ross and Seang Lin Tan for CAD 0.46 million.

INVO Bioscience names Andrea Goren as chief financial officer

INVO Bioscience Obtains Regulatory Approval to Import INVOcell Into Mexico

INVO Bioscience Advances Commercialization into the European Fertility Market with Initial Orders of INVOcell (IVC) in Spain

INVO Bioscience Expands Distribution of INVOcell Into the Pakistan Infertility Market with Galaxy Pharma Ltd

INVO Bioscience, Inc. and idsMED Group Enter Distribution Agreement for Malaysia

INVO Bioscience, Inc., Annual General Meeting, Dec 28, 2020

Invo Bioscience's Common Stock Deleted from Other OTC

INVO Biosciences Announces the Appointment of Jeffrey J. Segal as a Director of the Company

INVO Bioscience, Inc. Establishes Joint Venture to Operate INVOcell Fertility Clinics in Mexico

INVO Bioscience, Inc Announces Board Changes

INVO Bioscience, Inc. announced that it has received $3.49484 million in funding

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Analisi della pista di contanti

Scoprire le aziende sane